NANI Research
MORE exciting news for our IgAN patients! Last month, Novartis received FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN).
Last week, Travere Therapeutics Announced Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy. Click here for full press release: https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announ ces-full-fda-approval-filsparir#:~:text=SAN%20DIEGO%20%2C%20Sept.%2005%2C,at%20 risk%20of%20disease%20progression
NANI played a key role in both these groundbreaking studies, bringing novel treatment options to patients. This success is thanks to your referrals, patient support, and our research team, especially lead coordinator Swarnam Chiramel, PhD.
While these are a significant achievements, we continue to seek better treatments for IgAN and other kidney diseases. For questions about the study, other trials, or IgAN, contact Suneel Udani, MD, at sudani@nephdocs.com or 773.272.6965.
Value Based Care
Welcome Baby Amara!
Jazmin Quinonez – Revenue Cycle Representative gave birth to a beautiful baby girl Amara Arabella Smith-Quinonez –
Born August 9,2024 weighed 4lb 7oz.
1 Year 5 Years 10 Years 20+ Years
Erica Harnung Adriana Perse Larisa Estudillo Hsien-TA Fang
Adriana Venegas Lynda Maurino Sejal Kalawadia
Yajayra Garcia Andrea Bondie
Dione Valentino Brittney Clark
Victoria Zubovich Haley Morin Ryan Weiss
Erin Sours
Delin Wang
September Birthdays.xlsx